Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation
- PMID: 10595918
- PMCID: PMC1866954
- DOI: 10.1016/S0002-9440(10)65507-1
Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation
Abstract
Patients with neurofibromatosis 1 (NF1) are predisposed to develop multiple neurofibromas (NFs) and are at risk for transformation of NFs to malignant peripheral nerve sheath tumors (MPNSTs). Little is known, however, about the biological events involved in the malignant transformation of NFs. We examined the CDKN2A/p16 gene and p16 protein in NFs and MPNSTs from patients with NF1. On immunohistochemical analysis, all NFs expressed p16 protein. The MPNSTs, however, were essentially immunonegative for p16, with striking transitions in cases that contained both benign and malignant elements. None of the benign tumors had CDKN2A/p16 deletions, whereas three of six MPNSTs appeared to have homozygous CDKN2A/p16 deletions. Methylation analysis and mutation analysis of CDKN2A/p16 in MPNSTs did not reveal any abnormalities. These results show that malignant transformation of NF is associated with loss of p16 expression, which is often secondary to homozygous deletion of the CDKN2A/p16 gene. The findings suggest that CDKN2A/p16 inactivation occurs during the malignant transformation of NFs in NF1 patients and raises the possibility that p16 immunohistochemistry may provide ancillary information in the distinction of NF from MPNST.
Figures
![Figure 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1866954/bin/jh1291969001.gif)
![Figure 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1866954/bin/jh1291969002.gif)
Similar articles
-
Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview.Hum Pathol. 2017 Sep;67:1-10. doi: 10.1016/j.humpath.2017.05.010. Epub 2017 May 24. Hum Pathol. 2017. PMID: 28551330 Free PMC article. Review.
-
The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics.Am J Pathol. 2016 Mar;186(3):464-77. doi: 10.1016/j.ajpath.2015.10.023. Epub 2015 Dec 28. Am J Pathol. 2016. PMID: 26740486 Free PMC article. Review.
-
A neurogenic tumor containing a low-grade malignant peripheral nerve sheath tumor (MPNST) component with loss of p16 expression and homozygous deletion of CDKN2A/p16: a case report showing progression from a neurofibroma to a high-grade MPNST.Int J Clin Exp Pathol. 2015 May 1;8(5):5113-20. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26191206 Free PMC article.
-
Adhesion molecule L1 is down-regulated in malignant peripheral nerve sheath tumors versus benign neurofibromatosis type 1-associated tumors.Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Feb;113(2):239-44. doi: 10.1016/j.tripleo.2011.04.019. Epub 2011 Aug 11. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012. PMID: 22677742
-
Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.Genes Chromosomes Cancer. 2011 Dec;50(12):1021-32. doi: 10.1002/gcc.20921. Epub 2011 Aug 24. Genes Chromosomes Cancer. 2011. PMID: 21987445
Cited by
-
Case report: Atypical neurofibromatous neoplasm with uncertain biological potential of the sciatic nerve and a widespread arteriovenous fistula mimicking a malignant peripheral nerve tumor in a young patient with neurofibromatosis type 1.Front Oncol. 2024 May 10;14:1391456. doi: 10.3389/fonc.2024.1391456. eCollection 2024. Front Oncol. 2024. PMID: 38800392 Free PMC article.
-
Malignant peripheral nerve sheath tumor (MPNST) and MPNST-like entities are defined by a specific DNA methylation profile in pediatric and juvenile population.Clin Epigenetics. 2024 Jan 4;16(1):9. doi: 10.1186/s13148-023-01621-7. Clin Epigenetics. 2024. PMID: 38178234 Free PMC article.
-
FOXM1 promotes neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor progression in a NUF2-dependent manner.Cancer Gene Ther. 2023 Oct;30(10):1390-1402. doi: 10.1038/s41417-023-00645-8. Epub 2023 Jul 24. Cancer Gene Ther. 2023. PMID: 37488294
-
A chance to cut is a chance to cure: complete resection of an atypical neurofibroma prevents further progression to malignancy.Childs Nerv Syst. 2023 Nov;39(11):3301-3304. doi: 10.1007/s00381-023-06029-5. Epub 2023 Jun 21. Childs Nerv Syst. 2023. PMID: 37344677
-
Cell-Free DNA Liquid Biopsy: The Epitome of Personalized Precision Oncology.Radiat Res. 2023 Jul 1;200(1):92-95. doi: 10.1667/RADE-23-00044.1. Radiat Res. 2023. PMID: 37084268 Free PMC article. No abstract available.
References
-
- Karnes PS: Neurofibromatosis: a common neurocutaneous disorder. Mayo Clin Proc 1998, 73:1071-1076 - PubMed
-
- Zöller MET, Rembeck B, Odén A, Samuelsson M, Angervall L: Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 1997, 79:2125-2131 - PubMed
-
- : National Institutes of Health Consensus Development Conference: Neurofibromatosis Conference Statement. Arch Neurol 1988, 45:575-578 - PubMed
-
- Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM: Malignant peripheral nerve sheath tumors. A clinicopathlogic study of 120 cases. Cancer 1986, 57:2006-2021 - PubMed
-
- von Deimling A, Krone W, Menon AG: Neurofibromatosis type 1: pathology, clinical features and molecular genetics. Brain Pathol 1995, 5:153-162 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous